Moors & Cabot’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $402K | Sell |
645
-158
| -20% | -$108K | 0.02% | 636 |
|
|
2026
Q1 | $620K | Buy |
803
+18
| +2% | +$13.8K | 0.03% | 490 |
|
|
2025
Q4 | $606K | Buy |
785
+72
| +10% | +$48.9K | 0.03% | 485 |
|
|
2025
Q3 | $401K | Sell |
713
-5
| -0.7% | -$2.83K | 0.02% | 588 |
|
|
2025
Q2 | $377K | Sell |
718
-127
| -15% | -$70.9K | 0.02% | 583 |
|
|
2025
Q1 | $536K | Buy |
845
+60
| +8% | +$41.3K | 0.03% | 469 |
|
|
2024
Q4 | $559K | Sell |
785
-12
| -2% | -$10.1K | 0.03% | 469 |
|
|
2024
Q3 | $838K | Sell |
797
-19
| -2% | -$21.1K | 0.04% | 380 |
|
|
2024
Q2 | $858K | Sell |
816
-50
| -6% | -$48.5K | 0.05% | 340 |
|
|
2024
Q1 | $834K | Buy |
866
+25
| +3% | +$23.8K | 0.05% | 349 |
|
|
2023
Q4 | $739K | Buy |
841
+2
| +0.2% | +$1.65K | 0.05% | 340 |
|
|
2023
Q3 | $690K | Buy |
839
+43
| +5% | +$33.8K | 0.05% | 346 |
|
|
2023
Q2 | $572K | Buy |
796
+2
| +0.3% | +$1.54K | 0.04% | 406 |
|
|
2023
Q1 | $652K | Buy |
794
+7
| +0.9% | +$5.28K | 0.04% | 356 |
|
|
2022
Q4 | $568K | Sell |
787
-9
| -1% | -$6.64K | 0.04% | 382 |
|
|
2022
Q3 | $548K | Sell |
796
-65
| -8% | -$40.9K | 0.04% | 370 |
|
|
2022
Q2 | $509K | Sell |
861
-286
| -25% | -$186K | 0.04% | 406 |
|
|
2022
Q1 | $801K | Sell |
1,147
-40
| -3% | -$25.3K | 0.05% | 344 |
|
|
2021
Q4 | $750K | Sell |
1,187
-168
| -12% | -$103K | 0.05% | 356 |
|
|
2021
Q3 | $818K | Buy |
1,355
+93
| +7% | +$57.7K | 0.05% | 319 |
|
|
2021
Q2 | $705K | Buy |
1,262
+13
| +1% | +$6.59K | 0.05% | 335 |
|
|
2021
Q1 | $585K | Buy |
1,249
+440
| +54% | +$214K | 0.04% | 354 |
|
|
2020
Q4 | $384K | Buy |
809
+29
| +4% | +$15.7K | 0.03% | 454 |
|
|
2020
Q3 | $437K | Buy |
780
+86
| +12% | +$52.1K | 0.04% | 361 |
|
|
2020
Q2 | $433K | Buy |
694
+150
| +28% | +$85.1K | 0.05% | 349 |
|
|
2020
Q1 | $264K | Buy |
+544
| New | +$224K | 0.04% | 417 |
|
|
2018
Q1 | – | Sell |
-600
| Closed | -$227K | – | 603 |
|
|
2017
Q4 | $227K | Buy |
600
+115
| +24% | +$46.6K | 0.03% | 483 |
|
|
2017
Q3 | $217K | Buy |
+485
| New | +$231K | 0.03% | 478 |
|
|
2016
Q2 | – | Sell |
-1,935
| Closed | -$711K | – | 545 |
|
|
2016
Q1 | $711K | Sell |
1,935
-91
| -4% | -$37.5K | 0.13% | 203 |
|
|
2015
Q4 | $1.09M | Sell |
2,026
-558
| -22% | -$302K | 0.2% | 139 |
|
|
2015
Q3 | $1.21M | Buy |
2,584
+178
| +7% | +$95.6K | 0.22% | 119 |
|
|
2015
Q2 | $1.23M | Buy |
2,406
+41
| +2% | +$20K | 0.2% | 124 |
|
|
2015
Q1 | $1.08M | Buy |
2,365
+370
| +19% | +$157K | 0.18% | 137 |
|
|
2014
Q4 | $815K | Sell |
1,995
-25
| -1% | -$9.83K | 0.14% | 172 |
|
|
2014
Q3 | $730K | Sell |
2,020
-100
| -5% | -$33.5K | 0.12% | 186 |
|
|
2014
Q2 | $595K | Buy |
+2,120
| New | +$628K | 0.1% | 230 |
|
Other funds holding REGN
Moors & Cabot's REGN Position: Q2 2026 in Review
Moors & Cabot reduced its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, selling an estimated $108K and leaving 645 shares worth $402K. The position accounts for 0.02% of the portfolio, ranked #636.
Moors & Cabot first reported a position in REGN in Q2 2014 and has held it in 36 quarters since. The position peaked at $1.23M in Q2 2015. 788 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Moors & Cabot held 645 shares of Regeneron Pharmaceuticals worth $402K as of Q2 2026.
- Moors & Cabot sold 158 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $108K.
- Regeneron Pharmaceuticals made up 0.02% of Moors & Cabot's portfolio in Q2 2026, its #636 holding.
- Moors & Cabot first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 36 quarters since.
- Moors & Cabot's Regeneron Pharmaceuticals position peaked at $1.23M in Q2 2015.
- 788 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.